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Abstract: Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) are able to
promote the survival of multiple neuronal populations in the body and, therefore, hold considerable
promise for disease-modifying treatments of diseases and conditions caused by neurodegeneration.
Available data reveal the potential of GFLs for the therapy of Parkinson’s disease, neuropathic pain
and diseases caused by retinal degeneration but, also, amyotrophic lateral sclerosis and, possibly,
Alzheimer’s disease. Despite promising data collected in preclinical models, clinical translation of
GFLs is yet to be conducted. The main reasons for the limited success of GFLs clinical development
are the poor pharmacological characteristics of GFL proteins, such as the inability of GFLs to cross
tissue barriers, poor diffusion in tissues, biphasic dose-response and activation of several receptors in
the organism in different cell types, along with ethical limitations on patients’ selection in clinical trials.
The development of small molecules selectively targeting particular GFL receptors with improved
pharmacokinetic properties can overcome many of the difficulties and limitations associated with the
clinical use of GFL proteins. The current review lists several strategies to target the GFL receptor
complex with drug-like molecules, discusses their advantages, provides an overview of available
chemical scaffolds and peptides able to activate GFL receptors and describes the effects of these
molecules in cultured cells and animal models.
Keywords: glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs), receptor tyrosine
kinase Rearranged in Transfection (RET); RET agonist; GFL mimetic; small molecule; Parkinson’s
disease; neuropathic pain; neurodegeneration; retinitis pigmentosa
1. Introduction
Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) include three other
structurally related proteins in addition to GDNF: neurturin (NRTN), artemin (ARTN, also known
as enovin and neublastin) and persephin (PSPN) and, also, a distant member, growth differentiation
factor-15 (GDF15) [1,2]. They all play a role in the development and maintenance of the nervous
system, and GDNF is also important for kidney development and spermatogenesis [1,3,4]. GDF15 is
involved in appetite control [5–8].
The founding member of GFLs, GDNF, was discovered as a potent survival factor for dopamine
neurons [9], and, therefore, it was tested in several clinical trials in patients with Parkinson’s disease
(PD), as PD is characterized by the profound degeneration of dopamine neurons in the brain, resulting
in motor symptoms in the disease [10–15]. The efficacy of another GFL supporting dopamine neurons,
NRTN, delivered via gene therapy-based approach was also evaluated in PD patients [16–18]. However,
the results of these clinical trials remain controversial; while, in small-scale open label ones, the positive
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effects of such treatments were seen, large-scale trials failed to reach their primary efficacy end point.
The reasons explaining the inefficiency of GFLs in PD are reviewed in detail elsewhere [19,20] and are
mainly related to the inability of these proteins to cross through the blood–brain barrier and spread
into tissues. These issues make it necessary to deliver GFL proteins directly into the brain to the target
region of the midbrain dopamine neurons by means of complicated and expensive stereotaxic surgery,
which limits the selection of patients into clinical trials to the ones with late-stage PD. However,
late-stage PD patients have very little remaining target neurons to be supported and restored by
GFLs [21–23]. GFLs are able to support the survival of remaining neurons, regenerate their axons,
restore the damaged ones (Figure 1A) and improve the functional activity of viable neurons. However,
GFLs are unable to revive dead cells or produce new neurons. Therefore, the treatment with GFLs
should start as soon as possible, preferably immediately upon diagnosis, which is impossible—or,
at least, immensely difficult—in PD patients at the moment due to ethical restrictions on brain surgery
in early stage PD patients.
Figure 1. The biological effects of glial cell line-derived neurotrophic factor family ligands (GFLs)
in the adult organism and potential pathological conditions that these proteins may cure. (A) GFLs
support and restore degenerating neurons of different types. (B) GFLs may reduce the degeneration of
retinal cells and, therefore, have potential in the treatment of retinitis pigmentosa; support the survival
and guide migration of olfactory, dopamine and enteric neurons and may alleviate nonmotor and
motor symptoms of Parkinson’s disease; support the survival and functioning of sensory neurons,
thus reducing neuropathic pain symptoms, and are important for the survival of motoneurons,
thus having the potential to alleviate amyotrophic lateral sclerosis. Outside the nervous system,
glial cell line-derived neurotrophic factor (GDNF) is important for spermatogenesis and can have
potential in the treatment of male infertility or the development of male contraceptives. GFLs have
effects in sympathetic and parasympathetic neurons affecting multiple body functions. persephin
(PSPN) and its functional receptor are expressed in the thyroid gland and has a role in thyroid cancer.
Growth differentiation factor-15 (GDF15) has a role in regulating the immune system and metabolic
conditions. Neurturin (NRTN) supports β cells in the pancreas, but this effect is indirect. GDNF is also
important for kidney development in fetuses, but in adult organisms, its role for kidneys has not been
shown. Created with BioRender.com.
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The characteristic histopathological feature of PD is the presence in the brain of protein aggregates
called Lewy bodies, the main component of which is alpha-synuclein [24–26]. Recent data indicate that
the activation of GFL-dependent signaling can prevent the progression of alpha-synuclein pathology
in the brain [27].
ARTN, which has a well-established function in sensory neurons, was tested in patients with
neuropathic pain (NP) [28–30] and showed promising results in patients with painful lumbosacral
radiculopathy nonresponsive to at least two standard treatments [30]. However, in this trial, the dose
response to ARTN was biphasic, and the lowest dose provided the highest pain relief, while the
second most efficient dose was the highest one. This kind of dose-response relationship, along with
the reported side effects and potential of the ARTN to attach to extracellular matrix components,
producing high point concentrations and restricting tissue spreading, complicate the clinical use of the
ARTN protein.
Due to the capability to support motoneurons, GDNF has also been tested for the ability to slow
down the progression of amyotrophic lateral sclerosis (ALS), an incurable disease with very poor
prognosis and an average survival below five years after the diagnosis [31]. In patients suffering from
ALS, motoneurons in the brain and spinal cord degenerate and die. This leads to progressive muscle
atrophy and, finally, to respiratory failure, which is the most common cause of the death in ALS [32,33].
In some studies in animal models of ALS, GFLs improved the disease manifestations, although the
effect could be dependent on the delivery site, concern only some symptoms and be variable in the
degree of improvement [34–36], complicating the interpretation of the data and clinical translation.
GDNF delivered to patients using stem cells was found to be safe and well-tolerated in a recent
small-scale clinical trial, but the efficacy data are yet to be published [37]. Taking into account the
poor diffusion of GFL proteins in the tissue [38] and widespreadness of ALS pathology, selecting the
delivery paradigm for GFLs in ALS is especially difficult.
Retinitis pigmentosa is a hereditary eye disease characterized by the degeneration of retinal cells,
resulting in a loss of the peripheral vision at first and blindness when the disease progresses [39].
The data on the role of GDNF in retinal cell survival are controversial, but in some studies in animal
models, the positive effects of this protein were seen [40,41]. In retina, GFL receptors are expressed
in Müller cells, the principal glial cells in this tissue, which have supportive and neuronal activity
modulating functions [42]. GFLs delivered to an eye exert neuroprotective effects in photoreceptors
indirectly via the activation of Müller cells that secrete other trophic factors necessary for the survival
of retinal cells, such as fibroblast growth factor-2 [43].
GDNF also has a potential for the treatment of substance (drug) abuse and dependence via
its effects in the dopamine system [44,45]. GFLs may support basal forebrain neurons [46] and
promote dendrite arborization and synapse formation by hippocampal neurons [47], which degenerate
in Alzheimer’s disease (AD), although proof-of-concept for this indication needs further validation.
The lentiviral vector-encoded GDNF delivered into the hippocampus before the onset of symptoms
preserved the memory and learning ability in a mouse model of AD [48]. However, further studies are
needed to understand if the positive effects of GFLs can also be seen in mice with established AD and
elucidate the mechanism of action of GFLs in this model. Human data for the conditions listed above
are not yet available. GFLs exert trophic functions in the neurons belonging to autonomic nervous
system (sympathetic, parasympathetic and enteric), which are important for multiple body functions,
including digestion, breathing control, sweating, penile erection, etc. [4,49–52], which provides
interesting opportunities for further therapeutic developments. The use of GFLs proteins in associated
conditions is complicated because of their poor diffusion, but alternatives with improved properties
can be considered.
Important to mention is that, in many diseases caused by neuronal degeneration or damage,
neuroinflammation plays a prominent role [53–55]. A characteristic feature of neuroinflammation is
an activation of microglial cells in the nervous system. Recent data indicate that microglial cells express
GFL receptors, and GFLs can reduce microglia activation by inhibiting p38 MAPK signaling [56].
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Therefore, targeting GFL receptors can also diminish the deteriorative effects of microglial cells
in neurodegenerative disorders and chronic pain. Important to remember, however, is that microglial
cells can play not only proinflammatory but, also, an anti-inflammatory, protective role in the nervous
system, depending on their phenotype [57,58]. Further studies are needed to characterize the influence
of GFLs on specific subtypes of inflammatory cells and the consequences of such effects on the tissue
and organism levels.
GDF15 is aside from the other GFLs in its function. While it is important for the survival of motor,
sensory and dopamine neurons [59–61], it plays a role in the inflammatory and cardiovascular systems,
exerts nephroprotective effects and it has attracted major attention in the recent three years as a factor
controlling appetite [5–8,62].
GDF15 overexpression or infusions of recombinant growth factor resulted in a decrease in food
intake, improved glucose tolerance and, also, stimulated weight loss in mice fed by both standard
and high-fat diets [6,63,64]. The prevalence of overweight, obesity, metabolic diseases and associated
comorbidities is rising all over the world with a speed that made it be referred to as global pandemic.
According to the data provided in a systematic analysis for the Global Burden of Disease Study 2013,
36.9% of adult men and 38% of women in the world have a body mass index ≥ 25 kg/m2 [65].
The proportion of overweight children is also rising and exceeds 10% in developed and 20%
in developing countries [65]. Obesity treatments with proven efficacy include invasive gastric
bypass surgery and the lipase inhibitor orlistat, which works only in a subset of patients [66]. Therefore,
new noninvasive drugs to treat obesity are in high demand, and GDF15 appears as an attractive
therapeutic option [67]. Interestingly, NRTN supports pancreatic β cells and, thus, may be useful in the
management of diabetes [68]. This review focuses mainly on the role of GFLs in neurodegeneration;
extensive data on GDF15 functions in obesity and NRTN in diabetes are provided elsewhere [5–8,62,68].
To summarize, GFLs have a clear therapeutic potential for disease modification in several diseases
and conditions caused by neurodegeneration (Figure 1B). However, their clinical use is complicated
because of poor pharmacokinetic characteristics, high price, variability in biological activity between
batches, instability and immunogenic potential [10,13,69]. Besides, at least some neurodegenerative
disorders are characterized by widespread pathologies. For example, PD patients, in addition
to the degeneration of midbrain dopamine neurons, have other neuronal populations affected,
e.g., enteric neurons, noradrenergic neurons, etc. In Alzheimer’s disease, neurons in several brain
regions die. Sensory and motor neurons, degenerating in NP and ALS, are also located in different
parts in the body. GFLs have a high binding affinity to the extracellular matrix, and therefore,
their diffusion in the organism is limited [38]. Alternatives such as more diffusible neurotrophic factors,
peptides and peptidomimetics, as well as small molecules targeting GFL receptors, may provide
valuable tools to utilize GFLs’ potential to combat neurodegeneration and support the survival of
different neuronal populations in different parts of the body. The current review will describe peptides
and small molecules mimicking the biological effects of GFLs in cultured cells and animal models
of relevant neurodegenerative diseases and discuss their advantages and limitations for the therapy
of neurodegeneration.
2. Main Text
2.1. GFL Receptors and Signaling
The summary of GFL receptors and signal transduction events is presented in Figure 2. The main
receptor complex transmitting GFLs signals in the organism consists of glycosylphosphatidylinositol
(GPI)–anchored coreceptors GDNF family receptor alpha (GFRα1-4) or a transmembrane GDNF family
receptor alpha-like protein (GRAL) and a transmembrane receptor tyrosine kinase RET (REarranged
in Transfection). RET transfers signals into the cell and is shared by all five GFLs, while GFRα1-4
and GRAL function as ligand-binding subunits and are selective for individual members of GFLs.
GDNF binds with the highest affinity to GFRα1, NRTN to GFRα2, ARTN to GFRα3, PSPN to GFRα4
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and GDF15 to GRAL. In addition, GDNF can also interact with GFRα2 and NRTN, ARTN and PSPN
with GFRα1, although with a lower affinity than with the cognate coreceptors [38]. The formation
of a tripartite signaling complex that includes dimeric GFL, two molecules of GFRa or GRAL and
two molecules of RET results in the phosphorylation of tyrosine residues in the RET cytoplasmic
kinase domain. Phosphorylated tyrosines serve as docking sites for adapter molecules, such as Shc2
family members. Binding of adapter proteins to phosphorylated tyrosine residues in RET is followed
by the activation of intracellular signaling cascades such as MAPK/ERK, PI3K/AKT, JNK and Src.
These events play an important role in the survival of neurons, neurite outgrowth, neuronal migration,
the differentiation of neuronal precursors and other processes important for the functioning and
integrity of the nervous system [1]. In addition, an enzyme PLCγ can bind to phosphotyrosine residue
1015 in the RET kinase domain, become activated and trigger intracellular signaling events promoting
the survival and neurite outgrowth, at least in certain neuronal populations [70]. The activation of RET
by GDF15 via GFRAL occurs in neurons located only in two regions of the brainstem and is important
for appetite control [5–8,62].
Figure 2. Glial cell line-derived neurotrophic factor family ligands (GFLs) signaling. The main
signaling receptor for GFLs is receptor tyrosine kinase RET (REarranged in Transfection), which they
activate upon binding to a glycosylphosphatidylinositol (GPI)-anchored coreceptor GDNF family
receptor alpha (GFRα) or transmembrane GFRAL. RET subsequently activates classical receptor
tyrosine kinase signaling pathways such as MAPK, AKT, JNK and Src, which are important for the
cell survival and neurite outgrowth. In addition, GFLs in the presence of GFRα can signal via the
neural adhesion molecule (NCAM) associated with the Fyn kinase, promoting cell migration and
neurite outgrowth. GFLs via NCAM can also indirectly activate the fibroblast growth factor receptor
(FGFR). Finally, GFLs can bind syndecan-3 and activate the Src pathway, contributing to neuronal
precursor migration. Please, notice that the cognate GFRα receptor for persephin (PSPN) contains only
two extracellular cysteine-rich domains. For simplification, this is not reflected in the scheme. Solid
arrows indicate direct interactions and subsequent events, dotted arrows—indirect activation of certain
pathways. GDNF—glial cell line-derived neurotrophic factor, NRTN—neurturin and ARTN—artemin.
Created with BioRender.com.
To date, it is not clear if the GFRα1/RET complex is preassembled on the cell membrane or its
assembly starts from the interaction of the ligand with GFRα and the subsequent recruitment of
RET [71]. Structurally, the most striking difference in the signaling complex formed by RET different
ligands and coreceptors is the angle between the ligand monomers in the tripartite complex, which is
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the most acute in the GDF15/GRAL/RET complex and the widest in the GDNF/GFRα/RET complex [2].
The shape of the angle can influence the speed and duration of the intracellular signaling cascades’
activation [72] and, thus, fine-tunes the cellular response of individual members of the GDNF family.
In addition to RET, GFLs can also signal via the neural cell adhesion molecule (NCAM) and
promote the migration of Schwann cells and neurite outgrowth from cortical and hippocampal neurons
in the absence of RET, as well as influence the migration of neuronal progenitors along the rostral
migratory stream [73]. NCAM is constitutively associated with the cytoplasmic Fyn kinase, which,
upon stimulation, activates the focal adhesion kinase (FAK), followed by MAPK/ERK signaling cascade
activation and can also activate the fibroblast growth factor receptor (FGFR) [73,74]. While GFLs can
bind to NCAM itself [73,74] with a low affinity, the presence of GFRα greatly potentiates this binding
and is absolutely required to trigger signal transduction in the cells [73]. Another molecule transmitting
GFLs signals into cells independently of GFRα coreceptors is a heparin sulfate proteoglycan called
syndecan-3. GDNF interactions with syndecan-3 activate intracellular kinase Src and stimulate neurite
outgrowth from embryonic hippocampal neurons and the migration of GABAergic cortical neuronal
precursors [38].
RET and GFRα coreceptors are expressed in a number of GFL responsive neurons, including
dopamine, sensory, motor, sympathetic, parasympathetic and enteric neurons. GFRαs are more widely
distributed in the nervous system than RET [75] and, apart from neurons, are also found in glial cells.
The expression of NCAM and syndecan-3 is rather ubiquitous in the nervous system. Pleiotropic effects
produced by GFLs in different cell types can result in adverse effects and complicate the analysis of
clinical trial data. Therefore, the development of small molecules or peptides selectively activating
certain GFL receptors or even certain signaling cascades may significantly reduce the number of side
effects in patients in clinical settings.
2.2. Small Molecules Positively Modulating GFL Signalling
The very first molecule, named XIB4035 (Figure 3), claimed to be an agonist of the GFRα1 coreceptor
and was discovered by a group of scientists from Taisho Pharmaceutical Co. Ltd. and published
in 2003 [76]. According to the authors, XIB4035 competed with radioactively labeled GDNF with an IC50
of 10.4µM, increased RET phosphorylation at concentrations starting from 12µM and dose-dependently
promoted neurite outgrowth from Neuro-2A cells, which endogenously expressed GFRα1 coreceptor
and RET [76]. The paper had a number of limitations—in particular, neither RET phosphorylation nor
neurite outgrowth data were quantified and analyzed using statistical methods. Moreover, for the RET
phosphorylation assay, the protein-loading control was not even presented. Cytotoxicity tests made by
the authors were short-term and, therefore, not very reliable. The absence of any data on the activity
of the discovered molecule in cells lacking GFRα1 and RET made it impossible to conclude on the
specificity of the compound.
Figure 3. Chemical structure of the positive allosteric modulator of GFL signaling,
the compound XIB4035.
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The follow-up paper has clearly demonstrated that XIB4035 is not actually an agonist of GFL
receptors but a positive allosteric modulator of GFL signaling; this molecule increased the level of
RET phosphorylation and prolonged the activation of this receptor by GDNF or ARTN, while having
little, if any, biological activity towards the GFRα/RET complex in the absence of these cognate ligands.
It was also demonstrated that the compound has at least some degree of selectivity towards RET, as it
failed to increase the signaling induced by the nerve growth factor (NGF) or brain-derived neurotrophic
factor (BDNF) via Tropomyosin receptor kinases (Trk) TrkA and TrkB, respectively. Despite the lack of
truly agonistic activity towards GFRα/RET, XIB4035 efficiently prevented and reversed small-fiber
neuropathy in animal models. The topical application of XIB4035 attenuated the loss of thermal
nociception in a genetic model of small-fiber neuropathy caused by expression of the dominant
negative mutant of the ErbB4 receptor in Schwann cells and in a streptozotocin (STZ)-induced model
of diabetes mellitus (DM). Treatment with this compound also prevented the destruction of Remark
bundles in sciatic nerves in ErbB4 mutant mice and reduced the loss of isolectin B4 (IB4)-binding fibers
in sensory neurons in the spinal cord; however, it had no effect on the density of intraepidermal nerve
fibers in diabetic animals. No significant side effects of XIB4035 in the experimental animals were
reported [77].
Interestingly, some naphthoquinone derivatives, discovered recently, are also able to increase the
trophic effects of GDNF in immortalized cells expressing GFRα1/RET [78]. The further optimization of
such compounds could result in the development of a novel class of clinically useful positive allosteric
modulators of GFL signaling.
The data presented in this section indicate that targeting RET signaling with a small molecular
weight positive allosteric modulator has potential in the treatment of neuropathy [77,79]. However,
the need for the presence of endogenous ligands can limit the use of such molecules to the cases
with mild neuronal degeneration. XIB4035 was tested upon application to the local “affected region”,
but this may be complicated in centrally manifested diseases such as PD and ALS, in which the diseased
neurons may have lost connection with the regions producing GDNF. This issue can preclude the use
of positive allosteric modulators for the treatment of these disorders. It was also shown that XIB4035
can increase RET signaling induced by direct RET agonists that do not require the GFRα1 coreceptor to
elicit signaling [78]. This raises an interesting question of the actual target of XIB4035 or whether it can
support the hypothesis of the existence of a preformed GFRα/RET complex in cells.
2.3. Small Molecules Targeting RET
Three structurally different chemical scaffolds (piperazine-sulfonamides, quinolines and
hydroxynaphthalene) targeting RET directly have been discovered in high-throughput screening
campaigns (Figure 4). All of these compounds were shown to selectively increase RET phosphorylation
and to activate RET-dependent intracellular signaling cascades, such as MAPK and AKT in cultured
immortalized cells [78,80–83]. These compounds do not activate TrkA and TrkB or TrkA and
TrkB-dependent signaling and do not support the survival of neurons lacking RET [78,80–83].
Figure 4. Chemical structures of RET agonists belonging to piperazine-sulfonamides (A); quinoline (B)
and hydroxynaphthalene (C) scaffolds.
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Compounds belonging to the piperazine-sulfonamide class of RET agonists, BT13 (Figure 4A)
and its derivatives, BT18 and BT44, supported the survival of and/or promoted neurite outgrowth
from cultured sensory neurons, alleviated hypersensitivity in animal models of neuropathic pain
and protected/restored damaged sensory neurons in vivo. In healthy animals, these compounds
did not influence the pain thresholds. BT13 and BT18 were tested in a spinal nerve ligation (SNL)
model of neuropathic pain using a neuroprotective paradigm, e.g., a treatment with compounds was
initiated immediately after the injury [83,84]. BT44 alleviated the established SNL-induced neuropathy
and restored injured neurons when given to animals several days after the lesion, which more
closely resembled the clinical situation than the neuroprotection paradigm. Moreover, it also reduced
hypersensitivity to mechanical and cold stimuli in animals with STZ-induced DM. SNL leads to
a significant reduction in the expression of sensory neuron markers, such as IB4 for nonpeptidergic
neurons and the calcitonin gene-related peptide (CGRP) for peptidergic neurons located in the dorsal
root ganglia. RET is expressed in the majority of IB4-positive neurons and in a portion of CGRP-positive
neurons. The treatment with BT13, BT18 and BT44 protected/restored both IB4 and CGRP-positive
neurons in the SNL model of neuropathic pain, similarly to ARTN [85,86] and, also, stimulated
MAPK/Erk and Akt signaling in the sensory neurons [83,84]. We did not see neuronal degeneration
in DM animals in our experiments, probably because, for ethical reasons, the monitoring period was
rather short (max. of six weeks; afterwards, the animals had to be terminated due to poor conditions and
weight loss). However, GDNF was also able to normalize the neuronal activity in sensory neurons [87],
so possibly, in DM animals, BT44 worked via this mechanism [88].
BT13 and B44 also support the survival of cultured dopamine neurons RET-dependently and
protect them from death induced by dopaminergic toxins, such as 1-methyl-4-phenylpyridinium
and 6-hydroxydopamine [82] (Renko et al., submitted). BT13 was shown to stimulate the release
of dopamine in the brain in experimental animals when given intracranially or systemically. It also
activated prosurvival signaling cascades in mouse striata [82]. BT13 and BT44 alleviated motor
symptoms in a rat model of PD in neuroprotective and neurorestorative paradigms, respectively.
A trend to increase the density of dopamine fibers was seen in the striata of rats treated with
these compounds [89]. BT compounds can cross through the blood–brain barrier with different
efficacy [82,83,89] (Renko et al., submitted). BT compounds are not cytotoxic in the doses below
50–100 µM, and prohibited activity in in vitro CEREP screening was not manifested. These compounds
were tolerated by experimental animals well. We observed no signs of acute toxicity, pain or weight
loss in mice and rats treated with BT compounds systemically or intracranially. A histopathological
analysis revealed that the main tissues and organs in treated animals looked normal. Using docking
and molecular dynamics studies, we showed that BT compounds likely bind to the GFRα1-binding
interface of RET and, thus, mimic a complex of GFRα with GFL [90].
Compounds belonging to quinoline/naphthoquinone and hydroxynaphthalene scaffolds activate
intracellular signaling (both MAPK/ERK and AKT signaling pathways) in the cells expressing RET but
not NGF receptor TrkA. The structure activity relationship analysis of naphthoquinone (Figure 5A) and
quinoline (Figure 4B) compounds revealed the positions and chemical moieties responsible for toxicity,
selectivity towards RET, potency and GFRα dependence. Hydroxynaphtalenes bind to the GFRα1/RET
complex competing with GDNF (Sidorova et al., unpublished), and their biological activity can be
reduced by the treatment with XIB4035. In retinal explants dissected from animals with a genetic
mutation, causing retinitis pigmentosa, compounds from both of these scaffolds diminish apoptosis.
When injected into the eyes of wild-type animals, these compounds activated intracellular signaling
cascades in RET-expressing Müller cells [78,81]. Strikingly, in retinal explants, the efficacy of these
compounds for the reduction of apoptosis exceeds that of GDNF [81], likely because tissue exposure to
the GDNF protein is low because of its high affinity to the extracellular matrix [81].
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Figure 5. Chemical structures of GFRα/RET agonists from naphthoquinone (A) and benzimidazole
(B) scaffolds.
2.4. Small Molecules Targeting GFRα Receptors
The analysis of the interacting amino acid residues in the crystal structure of the GDNF/GFRα1
complex resulted in the design of a chemical GFRα/RET agonist from the benzimidazole scaffold
(Figure 5B) [91]. This compound increased the level of RET phosphorylation and activated RET
signaling in the cells expressing GFRα1/RET but not RET alone. It is unknown if this compound
can also target GFRα2-4/RET complexes. Although promising as GFL mimetic acting through the
same receptors as GFL itself, this compound has very low biological activity and should, therefore,
be substantially optimized before it or its derivatives can progress to tests in animal models of
neurodegeneration [91].
Additionally, some naphthoquinones (see Section 2.3) activated RET-induced intracellular signaling
GFRα1-dependently. However, these compounds also had rather high toxicity, seen already in 1–10-µM
concentrations. The analysis of RET phosphorylation and intracellular signaling is conducted only
with a few minutes upon compound application; subacute toxicity often does not appear in such assays.
On the contrary, the analysis of neuronal survival in cultured cells and neurorestorative properties
of the compounds in animal models require prolonged exposure. Therefore, naphthoquinones were
not tested in primary neuron and animal models. Nevertheless, they have an interesting biological
activity profile, and their further optimization directed towards reduced toxicity may result in the
development of therapeutically useful molecules selective towards GFRα1.
2.5. Peptides Targeting NCAM and RET
A tetrameric peptide from the heel region of ARTN activating both NCAM and RET-dependent
signaling and a peptide from the heel region of GDNF activating NCAM-dependent signaling,
called artefin and gliafin, respectively, have been designed and tested in neuronal cells [74,92].
Artefin promiscuously binds to GFRα1–GFRα3 with high affinity, supports the survival of cerebellar
granule neurons upon KCl challenge and stimulates neurite outgrowth from these cells [92].
Gliafin induces neurite outgrowth from hippocampal neurons that express NCAM but not RET [74].
It is not known whether it can activate RET and bind to GFRα. The data regarding the biological
activity of these peptides in in vivo models are not available. It is also unknown if they can penetrate
tissue barriers; they are designed as four 15-mer peptides covalently bound via a lysine backbone
(Figure 6) and are, therefore, quite bulky. Artefin exhibited a survival-promoting activity in rather high
concentrations within a narrow range (1.2–12.6 µM), which can also complicate the clinical translation
of this peptide.
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Figure 6. Structure of artefin.
2.6. Peptides from the GDNF Proregion with an Unknown Mechanism of Action
A predicted endopeptidase cleavage product from the GDNF proregion called DNSP-11, a peptide
that includes 11 consecutive amino acid residues from the proregion, was discovered as a molecule
able to stimulate synaptic transmissions in hippocampal neurons [93]. Later, it was shown to have
trophic actions in dopamine neurons in vitro and in an animal 6-hydroxydopamine (6-OHDA) model
of PD [94]. An immunohistochemical analysis of rat brains revealed that this peptide, either as a free
form or a part of proGDNF, can be detected in SNpc, where it colocalizes with dopamine neurons,
olfactory bulbs, the cerebellum and locus coeruleus but not in the striatum. Exogenously delivered
DNSP-11 is taken up by dopamine neurons in the substantia nigra pars compacta and, possibly,
also by GABAergic neurons in the substantia nigra pars reticulata. DNSP-11 also supported the
survival and neurite outgrowth from cultured rat embryonic dopamine neurons, reduced the number
of apomorphine-induced rotations and increased the striatal dopamine content in an animal 6-OHDA
model of PD. Mechanistic studies, however, revealed that DNSP-11 signals via a different receptor
complex than GFRα1/RET, because it did not bind to GFRa1; its activity was not blocked by the kinase
inhibitor staurosporine, and the profile of the cellular targets of DNSP-11 was different from the one
seen for GDNF [94]. Importantly, DNSP-11 showed efficacy in the PD model with a severe lesion,
condition in which GDNF itself often fails to produce biological effects. Therefore, this peptide can be
promising for the treatment of late-stage PD patients. In this study, DNSP-11 was delivered directly
into the brain, and it is unknown if it can penetrate through the blood–brain barrier and reach target
neurons if injected systemically [94], but it was speculated that the systemic delivery of DNSP-11 will
be unsuccessful due to a short half-life of the peptide in rat plasma (<12 min) [95]. However, it was
shown that DNSP-11 retains its neuroprotective activity in the dopamine system in a 6-OHDA model
of PD when delivered intranasally [95].
2.7. Advantages and Limitations in the Use of Each Class of GFRα/RET and NCAM Modulators for the
Management of Neurodegeneration
Several classes of small molecules and peptides targeting different components of GFL-signaling
complexes were described in this review. They all show promise in the treatment of neurodegeneration
but all may have advantages and disadvantages for clinical use. First of all, we described here peptides
and small molecules. Peptides are generally better-tolerated and are often more specific, therefore
producing less adverse and off-target effects in the organism. We described here two peptides targeting
GFL receptors and one produced from GDNF’s proregion [74,92,94]. Peptides targeting GFL receptors
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gliafin and artefin [74,92] are rather bulky, being only slightly smaller compared to GDNF itself. It is
unclear if they cross the blood–brain barrier and spread in the tissues, as they have yet to be tested
in vivo. At least artefin seems to target both RET and NCAM, the later molecule with widespread
expression in the nervous system [92]. The side effect profile and tissue distribution of these peptides are
yet to be evaluated. DNSP-11 seems to be a promising alternative for further preclinical development,
as it is relatively small. The receptor and signaling mechanism for DNSP-11 is yet to be determined [94],
as well as the delivery strategy, as it is unlikely to produce sufficient brain exposure upon systemic
delivery due to its short half-life [95]. Possibly, it can be delivered intranasally [95].
Small molecules promoting the signaling activation or targeting components of GFL receptor
complexes can spread in the tissues better than peptides and original proteins; some were shown to
penetrate through the blood–brain barrier. Characterized compounds act via three different mechanisms:
by promoting GFL signaling, by targeting RET directly or by targeting GFRα. Compounds promoting
GFL signaling can be the most specific, as they require the presence of both endogenous ligands and
full receptor complexes to elicit biological effects [76,77]. However, this feature can limit their efficacy:
in many neurodegenerative disorders, neurons start to degenerate from axons, and the connection
between the tissue or structure where atrophic; however viable neurons locate and target tissues or
brain structures, producing the growth factor may be lost. It is also unclear if such compounds will
promote only biological effects mediated by GFRα/RET or also those mediated by GFRα/NCAM.
Small molecules targeting RET are well-characterized and include structurally diverse compounds.
They spread in the tissues and cross through the blood–brain barrier with different efficacy [78,81–84].
The main concern is the side effect profile, since they can activate RET in the absence of a GFRα
coreceptor. RET was originally discovered as proto-oncogene, and mutated forms of RET can
indeed cause cancer, mainly in the thyroid gland and adrenals [96,97]. However, it is important
to remember that ligand-induced RET activation and the activation of RET when it is mutated are
really different processes. Ligands activate RET transiently, which is followed by the internalization
of the ligand/receptor complex and either the degradation or recycling of the receptor stripped
from the ligand to limit uncontrolled signal proliferation. In addition, activation of the receptor
by the ligand triggers mechanisms of signaling silencing via, e.g., the activation of phosphatases
dephosphorylating the receptor [98] and other proteins in the signaling cascades. Mutated forms of
RET, on the other hand, are constitutively activated, and this activation exceeds activation caused
by the ligand many-fold. Furthermore, differently from wild-type RET that is activated exclusively
when it is located on the cell surface plasma membrane, oncogenic RET is already permanently active
in the process of protein maturation when it enters the endoplasmic reticulum, thus signaling in
different cellular compartments [99]. The activation starts at the moment of embryonic development
and results in cancer only after many years. Recent studies show that the overexpression of GDNF at
moderate levels in mice do not stimulate tumor formation [100], supporting the idea that transient
RET activation by GFL proteins or small molecular weight ligands is safe. In our own experiments
with RET agonists belonging to the BT scaffold, we have not observed tumor formations (or any other
serious adverse effects) in experimental animals during the monitoring period of several months [88,89]
(Renko et al., submitted). Further studies are needed, however, to exclude potential off-target mutagenic
and carcinogenic effects of available small molecules targeting RET.
Another potential target-related side effect of RET agonists is food intake suppression and
subsequent weight loss. GDF15/GRAL/RET signaling plays an important role in appetite control [5–8],
and attempts to identify druggable targets in this pathway and develop related novel treatments
for obesity or cancer-induced cachexia are ongoing [62,67]. GRAL expression is restricted in the
brain to the area postrema [6], where feeding centers of the brainstem are located. Interestingly,
weight loss was reported as a side effect of intraventricularly delivered high doses of GDNF in a clinical
trial in Parkinson’s disease patients [10]. The molecular mechanism of this GDNF action remains
unresolved, as under normal conditions, GDNF does not bind to GRAL, and GRAL is required for
appetite control effects mediated by GDF15/GRAL/RET [6]. The intraventricular administration of
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GDNF in primates and the nigral or hypothalamic overexpression of GDNF in rodents induced weight
loss most probably by the activation of corticotrophin-releasing hormone neurons located specifically
in the paraventricular nucleus of the hypothalamus. The activation of the hypothalamic pathway of
weight control required rather high levels of GDNF overexpression [101]. When GDNF was delivered
into putamen, it did not influence the weight of patients [13]; however, in this delivery paradigm, it is
unlikely to reach brain regions responsible for weight gain control [38,101–103].
In our experiments, direct RET agonists from the piperazine-sulfonamides scaffold (BT compounds)
did not influence body weights [83,88,89]. However, we either treated animals with these compounds
for a relatively short time (one-to-two weeks) or delivered them intermittently. Animals were not
obese and were fed by a standard non-obesogenic laboratory diet. We also noticed that the activation
of GRAL/RET signaling in a reporter gene-based system [104] required rather high concentrations of
recombinant GDF15 (Sidorova et al., unpublished observation). As the efficacy and potency of BT
compounds are lower than that of GFLs and the compounds are rapidly metabolized, it is possible that
they were insufficiently active to stimulate the hypothalamic pathway of weight gain control [102] and
to promote the activation of RET in the complex with GRAL. BT compounds bind on the interface of
GFRα and RET, as revealed by docking and molecular dynamics studies [90]. Therefore, it is possible
that the presence of GRAL blocks their binding site in RET and, thus, precludes the activation of the
weight control pathway in the brainstem.
Other scaffolds of RET agonists are yet to be tested in experiments with systemic delivery.
Further studies are needed to understand the potential of RET agonists to influence food intake
and weight gain in healthy and obese animals. This research can result in the development of
new treatments for obesity and excessive weight. Small molecules targeting GFRα seem, at a first
glance, to be more specific compared to RET. However, it is important to remember that GFRαs
have a wider expression pattern in the nervous system compared to RET. In particular, a subset of
sensory neurons in the dorsal root ganglia transmitting the signals from the cold stimuli express
GFRα3 but not RET [105,106]. In addition, GFRα3 is also expressed in non-neuronal cells, and this
may contribute to hypersensitivity to inflammatory stimuli (reviewed in [19]). In some neuronal
populations, e.g., in sensory neurons, specific GFRα coreceptors are expressed only is a subset of
RET-positive neurons. Therefore, compounds targeting specific coreceptors can have limited efficacy,
as they will only support and rescue a small portion of lesioned neurons. Available compounds
targeting GFRα either have poor biological activity or rather high cytotoxicity. They have to be thus
optimized first before their efficacy in living organisms can be evaluated.
To summarize, there are several mechanisms by which GFL-related signaling can be targeted to
prevent neurodegeneration. The best approach has yet to be determined. In preclinical animal
models and in clinical trials, low levels of GFLs produced positive effects in the organism,
eliciting neuroprotective or functional effects in certain neuronal populations in the absence of
serious adverse events [14,15,100,107], while a high-level continuous overexpression or infusion
produced a number of side effects [101,108]. The activation of certain neuronal populations in the body
by GFLs can be beneficial for patients, as, for example, in PD, where, in addition to target nigrostriatal
dopamine neurons, VTA dopamine neurons, noradrenergic neurons of the locus coeruleus and sensory,
enteric and olfactory neurons (among others) are affected. This gives rise to nonmotor symptoms
that are difficult to treat and impair the quality of life of the patient even more compared to motor
symptoms [109]. Many neuronal populations whose dysfunction produces nonmotor symptoms
express GFL receptors and can be supported by small molecules targeting them. However, GFL proteins
in high doses can also produce adverse effects, e.g., the overexpression of GDNF in the hypothalamus
resulted in anorexia and weight loss [101]. Therefore, it might be beneficial to limit the efficacy of
developed compounds and restrict their half-life in the organism, as well as deliver them intermittently.
Small molecules targeting RET are less potent and efficient than GDNF itself and do not produce
such high levels of downstream signaling activation in an integral assay with luciferase readouts [82].
They are short-living compounds [82,83] that can possibly be delivered once in a few days or even
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weeks, as the effects of a single GDNF injection into the brain in PD models or several ARTN injections
in patients made within the week can last for a long period of time (weeks or, even, months) [30]. Thus,
a delivery schedule and moderate level RET activation can provide a sufficient therapeutic window to
make compounds targeting RET efficient and safe for clinical use.
2.8. Other Possible Applications of Compounds Targeting GFL Receptors
So far, only a few compounds targeting GFL receptors have been tested in vivo in a limited number
of conditions related to neurodegeneration. In view of the supportive role of GFLs in a number of
other central and peripheral neurons, it is of immense interest to test developed compounds in in vivo
models of different conditions and disorders, including, but not limited to, models of AD, ALS,
erectile dysfunction, digestive tract motility disturbances, excessive sweating and salivation. In many
of these conditions, the proof of concept with exogenously delivered GFLs is difficult to establish
because of the widespread pathology and limited diffusion of GFL proteins in tissues. Small molecules
or peptides, distributing widely over the body and exerting the same effects as GFLs, may represent
interesting therapeutic options for the above indicated conditions.
3. Conclusions
Despite great promise in the treatment of neurodegenerative disorders and neuropathic pain,
the clinical development of GFLs have, so far, achieved only limited success. This is due to the
pharmacokinetics of these proteins, which are unable to cross tissue barriers and spread very poorly
into tissues. In classic neurodegenerative disorders such as Parkinson’s disease, this means that GFL
proteins have to be surgically delivered into the brain, and even in this case, they cover only a small
portion of the affected tissue, as they diffuse poorly. In NP and eye diseases, these proteins can be
delivered systemically or locally, respectively, but the target tissue exposure to GFL proteins remains
problematic. Therapeutic efficacy issues of GFLs can be solved by the development of alternatives with
better pharmacological characteristics. Several exciting molecules with improved clinical translation
potentials, such as chemical compounds and peptides, targeting components of GFL receptor complexes
have been described over the last two decades. At the moment, it is unknown which strategy would be
the best: positive allosteric modulation of GFLs signaling or targeting RET, NCAM or GFRa coreceptors.
Available molecules should be further optimized to improve their potency and other properties.
Moreover, their safety has to be evaluated in extensive preclinical experiments. However, available
data show that GFL receptors are druggable targets, and the modulation of their biological activity
may be beneficial for the survival and well-being of retinal cells and sensory, dopamine and possibly
other neuronal populations. Other major possible indications for the applications of such compounds
are ALS and obesity, where in vivo proof of concept is yet to be established. Trophic effects of GFLs
in the autonomic nervous system also justify testing molecules targeting GFL receptors in conditions
associated with intestinal tract motility, excessive sweating and salivation, erectile dysfunction, etc.
Despite promising preliminary data, many questions regarding the clinical translation of compounds
targeting GFL receptors remain to be answered. In particular, the administration regimen for such
compounds has to be carefully considered. Taking into account potential side effects as a result of
the continuous long-term activation of RET and recent clinical trials data with intermittent delivery,
we think that the best treatment paradigm will be systemic administration with regular intervals
(e.g., once-monthly or weekly). However, further research is needed to best utilize the potential of
GFLs and their receptors for the treatment of neurodegeneration and to establish a treatment paradigm
for the developed compounds.
4. Patents
M.S. is an inventor in a composition of matter patent on BT compounds US 8,901,129 B2 and
patent application US20200113895A1. A patent has been filed for a naphthoquinone scaffold of RET
agonists on behalf of Y.A.S., M.S. and others.
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